Junshi BIO proposes governance, incentive reforms, new share options

Junshi BIO is calling an extraordinary general meeting (EGM) on September 26, 2025, to vote on comprehensive governance and incentive overhauls. Key proposals include the election of an independent non-executive director and amendments to internal management policies. Significantly, the company seeks to change its registered capital from 985,689,871 yuan to 1,026,689,871 yuan, abolish the board of supervisors, and transfer its powers to an audit committee, alongside related updates to the articles of association and rules of procedures.

Further critical items on the EGM agenda involve the adoption of the 2025 A share option incentive scheme and the 2025 H share option incentive scheme. The A share scheme proposes granting 26,175,871 A share options, including 8,000,000 to chairman Mr. Xiong Jun at an exercise price of 46.67 yuan per A share. The H share scheme outlines a conditional grant of 13,210,000 H share options to seven executive directors and three other employee participants at an exercise price of HK$32.30 per H share. These schemes also entail the approval of assessment management measures and authorization for the board of directors to manage their implementation.